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Abstract
Urachal carcinoma (UrC) is a rare tumor with remarkable histological and molecular similarities to colorectal cancer (CRC).
Adenomatous polyposis coli (APC) is the most frequently affected gene in CRC, but the prevalence and significance of its
alterations in UrC is poorly understood. In addition, loss of phosphatase and tensin homologue (PTEN) was shown to be
associated with therapy resistance in CRC. Our primary aim was to assess specific genetic alterations including APC and
PTEN in a large series of UrC samples in order to identify clinically significant genomic alterations. We analyzed a total of 40
UrC cases. Targeted 5-gene (APC, PTEN, DICER1, PRKAR1A, TSHR, WRN) panel sequencing was performed on the Illumina
MiSeq platform (n = 34). In addition, ß-catenin (n = 38) and PTEN (n = 30) expressions were assessed by immunohistochemistry.
APC and PTEN genes were affected in 15% (5/34) and 6% (2/34) of cases. Two of five APC alterations (p.Y1075*, p.K1199*)
were truncating pathogenic mutations. One of the two PTEN variants was a pathogenic frameshift insertion (p.C211fs). In 29%
(11/38) of samples, at least some weak nuclear ß-catenin immunostaining was detected and PTEN loss was observed in 20%
(6/30) of samples. The low prevalence ofAPCmutations in UrC represents a characteristic difference to CRC. Based onAPC and
ß-catenin results, the Wnt pathway seems to be rarely affected in UrC. Considering the formerly described involvement of PTEN
protein loss in anti-EGFR therapy-resistance its immunohistochemical testing may have therapeutic relevance.
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Introduction
The urachus is an extraperitoneal fibromuscular band that
connects the bladder dome and the umbilicus. During fetal
development, the urachus ensures the communication be-
tween the forming bladder and the allantois. After the fourth
month of embryonic life, the urachus usually transforms into a
fibromuscular strand (i.e. median umbilical ligament). In up to
one third of adults, this obliteration can be incomplete
resulting in microscopic urachal residues. Incomplete regres-
sion of the urachal structure may lead to various diseases
including urachal cancer (UrC) [1, 2].
UrC is an extremely rare disease with an estimated annual
incidence of one in one million adults. The majority of UrC
present as adenocarcinomas (~90%) with mucinous, intesti-
nal, signet ring, not otherwise specified (NOS) or mixed his-
tology. Because of its hidden anatomical location, UrC is
mostly detected in progressed stages when patients present
with hematuria resulting from its invasion into the urinary
bladder. At this advanced stage, the overall 5-year survival
is only about 50% [3–5].
Although urachal and colorectal adenocarcinomas (CRC)
are different types of cancer, they share remarkable histopath-
ological and clinical similarities. Also, their immunophenotype
shows overlapping staining characteristics with only a few ex-
ceptions [4]. In contrast to CRC, the molecular background of
UrC is only poorly understood. Data on UrC’s mutational pat-
tern further highlighted its similarity to CRC with overlapping
mutational patterns such as in TP53,KRAS, SMAD4 andNRAS
[6–17]. On the other hand, later studies also identified some
significant molecular differences between UrC and CRC
[6–12, 14–18].
In CRC, the adenomatous polyposis coli (APC) tumor sup-
pressor gene has a critical role in the initiation of tumorigen-
esis. APC mutations lead to abnormal ß-catenin accumulation
in the nucleus. This nuclear ß-catenin gets in contact with a
member of the TCF/LEF family and acts as a transcriptional
regulator on specific proliferation-associated target genes.
APC mutations occur in more than 80% of CRC [17]. As a
consequence, nuclear ß-catenin expression can be observed in
the generality of CRC making ß-catenin a well established
diagnostic and prognostic biomarker in CRC [19, 20]. The
occurrence and role of APC-alterations and ß-catenin-expres-
sion are less well established in UrC.
Phosphatase and tensin homolog (PTEN) is a leading neg-
ative regulator of the PI3K signaling pathway and therefore
known as a tumorsupressor gene. Its inactivating genetic mu-
tations occur in up to 10% of CRCs [17]. In addition to genetic
loss, PTEN is frequently downregulated by epigenetic silenc-
ing, leading to loss of PTEN expression [21]. Loss of PTEN
protein expression was shown to be associated with resistance
to anti-epidermal growth factor receptor (EGFR) therapy [22],
while this therapy demonstrated effectiveness in UrC [14].
Therefore, we aimed to analyze relevant genetic alterations
including the APC and PTEN genes as well as to assess the
tissue protein expressions of β-catenin and PTEN in UrC.
Materials and Methods
Clinical Samples
Formalin-fixed paraffin embedded (FFPE) tumor tissues from
40 urachal adenocarcinoma patients were retrospectively col-
lected from nine academic centers. Clinicopathological and
follow-up data were retrieved from cooperating institutions
using a uniform datasheet. Histopathological evaluation was
performed according to criteria also adopted by the World
Health Organization [23]. The study was performed in com-
pliance with the Declaration of Helsinki and the institutional
ethics committee approved the study protocol (16–6902-BO).
Sample Preparation and Targeted Next-Generation
Sequencing
FFPE tumor tissue blocks were cut and 4 μm-thick slides were
stained with hematoxylin and eosin. Tumor containing areas
were marked by a pathologist (H.R.) and macrodissection was
performed. Sample preparation and targeted next-generation
sequencing were performed as previously described [7]. For
targeted sequencing, a customized panel was used containing
regions of interest. The customized panel contains exonic and
flanking intronic regions from 6 genes (APC: exons 1–16,
DICER1: exons 1–28, PRKAR1A: exons 1–11, PTEN: exons
1–9, TSHR: exons 1–10,WRN: exons 2–35). The regions were
covered by a total of 108 amplicons. In all runs, an average
coverage of approximately 5000x was obtained. Analyses
were performed using CLC Biomedical Genomics
Workbench.
Immunohistochemistry (IHC)
The ß-catenin-IHC (Ref: 503–2264, Zytomed Systems,
Berlin, Germany; pretreatment: CC1, 90 °C, 16 min; dilution:
1:1000, 24 min) analysis was performed on 38 FFPE tumor
UrC tissues while PTEN-IHC (clone: 138G6, Cell Signaling
Technology, Cambridge, UK; pretreatment: CC1, 90 °C,
32 min; dilution: 1:200, 24 min) analysis was done on 30
available FFPE tumor samples. For IHC assays, 3 μm thick
FFPE sections were cut. IHC was performed on a Ventana
Benchmark Ultra system (Ventana Medical Systems,
Tucson, AZ, USA) and visualization was conducted using
OptiView DAB System (Ventana Medical Systems).
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Statistical Analysis
Statistical analyses were conducted with SPSS software pack-
age (v24 Chicago, IL). Kaplan-Meier survival analyses with
the log-rank test were used to evaluate the impact of selected
variables on overall survival. Furthermore, univariable Cox
regression analyses were done. P values <0.05 were
accounted statistically significant.
Results
Cohort Characteristics and Primary Treatment
The median age of patients at diagnosis was 51.5 years (range
24–78). Twenty-three patients (58%) were male and 17 (42%)
were female. The most frequent symptom of UrC was
haematuria reported in 83% of patients. Other symptoms in-
cluded abdominal pain (10%) and palpable tumor mass (3%)
(Table 1).
All UrC were adenocarcinomas (ADC) mostly of the intes-
tinal subtype (48%) followed by the mucinous subtype (35%).
Dominant signet ring cell features (>50% of tumor cells) were
seen in 2 cases (5%) while calcification was observed in 4
cases (11%) (Table 1).
Based on its specific anatomical location and invasion pat-
tern, UrC requires a unique stage classification. The most
often used systems are the Sheldon andMayo staging systems
(23, 24). One patient was staged as Sheldon stage II (3%), 24
were stage III (63%) and 13 were stage IV (34%). According
to the Mayo system 10 UrCs were stage I (28%), 13 stage II
(36%), 4 stage III (11%) and 9 were stage IV (25%) tumors
(Table 1).
In our cohort, one third of patients had lymph node positive
or distant metastatic disease at initial diagnosis (14/40, 35%).
Data on surgical treatment were available for 35 patients.
Most patients (24/35, 69%) were treated with partial
cystectomy followed by radical cystecomy (8/35, 23%), and
transurethral resection (3/35, 9%), while removal of median
umbilical ligament with umbilicus has been performed in 52%
of cases (Table 1).
Genomic Alterations in Urachal Cancer
Sample purification in 34 of 40 cases yielded appropriate
amount and quality of DNA sample for sequencing analy-
sis. We analyzed the alterations of APC, DICER1,
PRKAR1A, PTEN, TSHR and WRN genes. The APC and
PTEN genes were affected in 15% (5/34) and 6% (2/34) of
cases. Two of the APC alterations (p.Y1075*; c.3225 T >
G, p.K1199*; c.3595A > T) were truncating mutations
resulting in a truncated and non-functional APC protein
and were therefore considered as pathogenic, while other
Table 1 Clinicopathological profile of 40 UrC cohort included in this
study
n = 40 (%)
Sex Male 23 58
Age (year) Median (Range) 51.5 (24–78)
Haematuria Yes 25 83
No 5 17
n.a. 10 –
Abdominal pain Yes 3 10
No 26 90
n.a. 11 –
Palpable tumor Yes 1 3
No 29 97
n.a. 10 –





Calcification Yes 4 11
No 34 89
n.a. 2 –










LN status LN+ 9 23
LN-/LNx 31 78
Distant metastasis M+ 11 28
M−/Mx 29 73
LN/M status LN/M+ 14 35
LN/M- / LN/Mx 26 65
Surgery TURB 3 9
Partial cystectomy 24 69
Radical cystectomy 8 23
n.a. 5 –
Umbilectomy Yes 16 52
No 15 48
n.a. 9 –
Abbrevations: NOS not otherwise specified, SRC signet ring cell carcino-
ma, LN lymp node, LN+ positive lymph node status, LN- negative lymph
node status, LNx unknown lymph node status,M+ positive distant meta-
static status, M- negative distant metastatic status, Mx unknown distant
metastatic status, TURB transurethral resection of bladder, n.a. not
available
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three APC alterations were annotated as benign variants
(p.L2722V; c.8164C > G, p.L666V; c.1996 T > G,
p.N862K; c.2586C > G) (Table 2). One of the two PTEN
alterations was a frameshift insertion, leading to a dysfunc-
tional protein (p.C211fs; c.631_632insG) and was classified
as a pathogenic mutation, while the other PTEN alteration
was considered as benign (p.R308C; c.922C > T) (Table 2).
In addition, DICER1 intronic alterations (c.4206 +
8_4206 + 9insTTGTG, COSM1666515) were found in
29% (10/34) of UrC cases.
ß-Catenin and PTEN Immunoexpression
Immunohistochemistry for ß-catenin was performed in 38
cases. Positive membranous and cytoplasmic ß-catenin immu-
nostaining was observed in 97% (37/38) of UrC samples. Any
amount of clearly discernible nuclear immunostaining for ß-
catenin was detected in 29% (11/38) of samples. In one of the
two cases with truncating APC mutation (p.Y1075*;
c.3225 T >G), nuclear expression of ß-catenin was observed.
PTEN loss was observed in 6 of 30 (20%) UrC samples
(Figs. 1 and 2).
Survival Analysis
The median overall survival (OS) was 34 months (range:
2–212 months) and the median progression-free survival
(PFS) was 22 months (range 0–117 months). Three-year
and five-year OS was 71% and 64%, respectively.
Postoperative progression was detected in 50% of cases
(16/31). At the time of data evaluation, 65% of patient
(22/34) were alive.
Neither APC nor PTEN mutations were associated with
OS, however these results must be interpreted with caution
as only two cases demonstrated APC and PTEN mutations
(Table 3) (Fig. 3a, c). Presence of nuclear ß-catenin and loss
of PTEN expressions were not associated with shorter OS
(p = 0.606 and p = 0.869) (Fig. 3b, d).
Discussion
It is well known, that mutations of the APC tumor suppressor
gene have a critical role already in early stages of CRC devel-
opment. The most important function ofAPC is to establish an
interaction with the ß-catenin protein, thus accelerating its
degradation and regulation of the cadherin-mediated cell–
cell adhesion system. Functional loss of APC leads to abnor-
mal ß-catenin accumulation and translocation from the plasma
membrane to the nucleus [20].
Singh et al. used a whole exome sequencing approach and
found APC mutations in 43% (3/7) of UrC samples. They
detected one sample with a nonsense mutation, one with a
frameshift mutation and one with a deletion. The frameshift
mutation and deletion caused dysfunctional APC proteins
[16]. Collazo-Lorduy et al. described truncated APC muta-
tions (R1450*, R554*) in 22% (2/9) of UrC samples using a
targeted exome sequencing approach [14]. In addition, Lee
et al. reported APC mutations in 18% (3/17) of UrC cases
including a frameshift deletion (K1444fs) and a stop-gain sin-
gle nucleotide variant (SNV) (E1093*) [10]. In the latest
study, Kardos et al. performed targeted exon sequencing of
12 urachal adenocarcinoma cases and found 3 of 12 samples
(25%) with APC mutations [9].
In our study, analyzing 34 UrC cases, deleterious alter-
ations of APC tumor suppressor gene were present in 2
UrC samples. Neither mutation has been previously report-
ed in UrC: p.Y1075* (c .3225 T > G), p.K1199*
(c.3595A > T). Both of these nonsense mutations are pre-
dicted to cause a truncated, dysfunctional APC protein.
Three additional alterations were considered benign.
Presence of potentially pathogenic APC mutations tended
to be associated with shorter OS, however, because of the
low number of cases with APC mutation, this correlation
has to be interpreted cautiously.
Summarizing our results with all currently available data
on APC status in UrC, an overall number of 14 of 141 (10%)
UrC samples exhibited APC alterations [6–16, 18, 24–26]
which is in clear contrast to the high APC mutational rate
(80%) found in CRC [17]. This finding represents a further
characteristic difference in the molecular taxonomy between
CRC and UrC. Therefore, our results demonstrate that the
Wnt pathway is probably less frequently involved in the path-
ogenesis of UrC compared to CRC.
ß-catenin is a well-established diagnostic and prognostic
biomarker in CRC. Physiologically, ß-catenin staining is re-
stricted to the membrane/cytoplasm and is involved in
cadherin-mediated cell-cell adhesion and gene transcription
regulation. Nuclear ß-catenin expression can be observed in
CRC [19]. Wong et al. demonstrated positive nuclear staining
for ß-catenin expression in the vast majority of colorectal ad-
enocarcinomas which reflects the high APC mutation rate
found in CRC [27].
Table 2 Detected genomic alterations in UrC
Gene Protein change Nucleotide change Prediction
APC p.L2722V c.8164C >G Benign
APC p.L666V c.1996 T >G Benign
APC p.Y1075* c.3225 T >G Pathogenic
APC p.N862K c.2586C >G Benign
APC p.K1199* c.3595A> T Pathogenic
PTEN p.R308C c.922C > T Benign
PTEN p.C211fs c.631_632insG Pathogenic
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In a recent review of the UrC literature including own data,
we found a low incidence of nuclear ß-catenin staining in UrC
(14%, 9/63) [4]. In the present study, we detected positive
nuclear ß-catenin immunostaining in 29% (11/38) of UrC
samples. In addition, ß-catenin nuclear expression was not
associated with adverse OS (p = 0.606). Interestingly, we ob-
served a nuclear ß-catenin localization only in one of the two
samples with truncating APC mutation. As a potential genetic
mechanism for ß-catenin nuclear accumulation, Alomar et al.
identified an activating mutation in exon 3 of CTNNB1 (ß-
catenin) gene which resulted in an amino acid change at phos-
phorylation sites of glycogen synthase kinase-3 (GSK-3β).
Failing of phosphorylation was found to decrease sequestra-
tion of β-catenin by APC [28]. This effect might explain our
finding with low APC mutational frequency but at the same
time surprising high rate (29%) of nuclear ß-catenin positivity.
It has also to be kept in mind that we used a 1% threshold for
calling a case positive in case of nuclear β-catenin staining. In
some cases, it is difficult to discriminate between a real nucle-
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Fig. 1 Comutation plot
summarizing the genomic
alterations for the 40 cases of UrC
and mapping them to various
clinicopathologic parameters. In
case of APC and PTEN, only
pathogenic mutations are shown.
Abbrevations: IHC:
immunhistochemistry, NOS: not
otherwise specified, SRC: signet
ring cell carcinoma, CM:
cytoplasmic/membranous
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cytoplasmic staining especially in smaller tumor cells (i.e.
signet ring cells).
The tumor suppressor PTEN is a negative regulator of the
PI3K signaling pathway. PTEN mutations occur in 4–10% of
CRC and were suggested as potential markers of response to
EGFR and mitogen-activated protein kinase (MAPK)
inhibitor-based targeted therapies [17]. Perrone et al. showed
that inactivation of PTEN protein by mutation (P103S, E99*)
or deletion (hemizygous) was responsible of anti-EGFR resis-
tance [29]. PTEN protein loss was detected in approximately
40% of all CRC patients, which is clearly higher compared to
the rate of genomic loss. This suggests that PTEN is more
frequently downregulated by epigenetic silencing. In accor-
dance, PTEN methylation was found to be significantly cor-
related with PTEN expression [21]. Similar to the findings at
the genomic level, Frattini et al. showed that loss of PTEN
protein expression was associated with non-responsiveness to
cetuximab [22].
In the literature, we found three whole exome sequencing
studies with an overall number of 19 UrC samples. None of
them reported any PTEN mutations [10, 14–16]. In addition,
none of the targeted sequencing studies reported any PTEN
mutations in UrC. Here, we identified a pathogenic frameshift
PTEN mutation (p.C211fs) in one of the 34 UrC cancer sam-
ples (3%), suggesting a low incidence for PTEN mutation in
UrC. Therefore, the PTENmutational frequency in UrC seems
to be similar to that of reported in CRC (4–10%) [17].
To the best of our knowledge, no published data is
available on PTEN protein expression in UrC. In the pres-
ent study, performing PTEN IHC analysis, we observed
PTEN protein loss in 20% of UrC cases (6/30), which is
somewhat lower than that of 30–40% described in CRC.
The low rate of PTEN loss at the DNA level, but relative
high rate at the protein level suggests that PTEN is
Fig. 2 A typical example of
strong membranous and
cytoplasmic ß-catenin
immunostaining in a case of UrC
with intestinal differentiation in a)
while in b) A case of mucionous
UrC additionally showed strong
nuclear ß-catenin
immunopositivity of most cancer
cell nuclei. In c) a case of UrC
(NOS) with expression of PTEN
is depicted while in d) another
case of UrC (NOS) showed loss
of PTEN-immunostaining with
internal positive control. a 200x,
b-d) 400x. Abbrevations: NOS:
not otherwise specified
Table 3 Univariate analysis
Variables Overall survival
n HR 95% CI P
Sheldon stage
I-III 25 ref.
IV 13 2.332 0.734–7.407 0.151
Mayo stage
I-II 25 ref.
III-IV 13 2.332 0.734–7.407 0.151
LN/M status
LN/M- or LN/Mx 18 ref.
LN/M+ 13 1.982 0.564–6.969 0.286
PTEN mutations
negative 32 ref.
positive 2 2.124 0.436–10.337 0.351
PTEN staining
present 24 ref.
absent 6 1.144 0.230–5.687 0.869
APC status
No mutation 32 ref.
Mutation 2 3.464 0.704–17.056 0.127
β-Catenin nuclear staining
negative 27 ref.
positive 11 0.722 0.209–2.500 0.607
Abbrevations: LN/M+ positive lymph node or distant metastasis status,
LN/M- negative lymph node and distant metastasis status, LN/Mx un-
known lymph node or distant metastasis status
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predominantly silenced by epigenetic downregulation in
UrC [21]. The high rate of PTEN protein loss in UrC
suggests that its immunohistochemical analysis may be
important in order to predict potential inresponsiveness
to anti-EGFR therapy. In contrast, the rare occurrence of
PTEN inactivating mutations suggests that these alter-
ations are less important to analyze when considering
the administration of an anti-EGFR drug, while activating
KRAS mutations are more common in UrC (28%) and are
clinically important negative predictors of anti-EGFR
therapy [6–16, 18, 24–26].
Conclusions
In summary, we analyzed a large cohort of UrC with a
targeted next-generation sequencing approach supplemented
with ß-catenin and PTEN immunohistochemical analyses.
Our results show that APC mutations are much less frequent
in UrC (10%) compared to CRC (80%) suggesting that the
Wnt pathway is involved in the pathogenesis of only a
relatively small portion of UrC. In addition, both UrC and
CRC have low rates genomic loss (3% and 4–10%) but rela-
tive high rates of PTEN protein loss (20% and 40%), suggest-
ing an epigenetic regulation for this gene in both tumor types.
Therefore, as the loss of PTEN protein expression was found
to be associated with resistance against anti-EGFR therapy, its
immunohistochemical testing should be considered when
planning anti-EGFR therapy. Our data provides further clues
for both the similarity (regarding PTEN) and difference (re-
garding APC) between UrC and CRC and suggest that these
tumor types are similar yet distinct on the molecular level.
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